Because we only included non-ischemic patients in this study, we did not observe a significant difference in troponin I concentrations between patients with high or low SDI.
We found no significant difference in troponin I concentrations between patients with low or high SDI (0.025 [0.09–0.05] vs. 0.035 [0.009 0.05] mg/mL, P = 0.247).
We found no evidence of higher IGF-I concentrations with this polymorphism.
Unexpectedly, there was no change in apoA-I concentrations with DERT.
With impairments of these signalling pathways also observed with age following muscle contraction (Fry et al., 2011), a recent study using mouse models attempted to recapitulate declining human serum IGF-I concentrations with age.
The present study was performed to examine circulating levels of leptin and IGF-I at the onset of COPD exacerbations (D1) and two weeks later (D15) and furthermore to investigate the relationship of plasma leptin and IGF-I concentrations with cytokine concentrations as a possible reflection of the enhanced inflammatory status observed during the COPD exacerbation.
The hypoalphalipoproteinemia observed in carriers of the L75P apoA-I variant is mainly due to a marked reduction in LpA-I concentration with no significant changes in LpA-I A-II LpA-I A-II
Our primary outcomes of interest were the association of 1) baseline Lp(a) concentration and 2) baseline apoC-III concentration with eGFR slope.
In our dataset, there was no evidence of increasing MDSC percentage or of arginase I concentration with stage (P = 0.51 and P = 0.53, respectively).
Single and multiple injections of recombinant human GH increased IGF-I concentrations, whereas treatment with a GHA lowered IGF-I in rabbits.
Binding assays were performed with VEGF binding chimeras by incubating a range of I-VEGF and I-VEGFf concentrations with Fc-VEGFR1, Fc-NP-1, or both in binding buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, and 1 mg/ml BSA) for 2 h at 4°C.
